This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jebbink, J. Articles by Domiati-Saad, R. Search for Related Content PubMed PubMed Citation Articles by Jebbink, J. Articles by Domiati-Saad, R.

JMD 2003, Vol. 5, No. 1
Copyright © 2003 American Society for Investigative Pathology & Association for Molecular Pathology

Development of Real-Time PCR Assays for the Quantitative Detection of Epstein-Barr Virus and Cytomegalovirus, Comparison of TaqMan Probes, and Molecular Beacons

Jiska Jebbink^*, Xin Bai^*, Beverly Barton Rogers^*, D. Brian Dawson^*, Richard H. Scheuermann^* and Rana Domiati-Saad

From the Department of Pathology and Laboratory of Molecular Pathology, * University of Texas Southwestern Medical Center, Dallas; and the Department of Pathology and Laboratory of Molecular Pathology, Baylor University Medical Center, Dallas, Texas

Human Epstein-Barr virus (EBV) and cytomegalovirus (CMV) can cause serious complications in immunocompromised patients. Rapid diagnosis of EBV and CMV infection is critical in the management of the disease so that anti-viral therapy can be started early. Here we describe the development of real-time PCR assays using TaqMan probes and molecular beacons and compare the performance of both assays with a well-established, validated, gel-based PCR method for the quantification of EBV and CMV in patients’ samples. The TaqMan and molecular beacon assays were linear between 10 to 10⁷ viral genomes/reaction. Both assays generated calibration curves with strong correlation and low intra-assay and interassay variation. Results of EBV and CMV viral load determination inpatient samples obtained by the gel-based and real-time PCR were very similar. The real-time PCR assays showed increases in viral load before clinical measures of viral disease and decreases in viral load during anti-viral therapy in two of six pediatric patients. The data indicate that these TaqMan and molecular beacon approaches are accurate, rapid, and reliable assays for the diagnosis and monitoring of EBV and CMV infections in patients.

This article has been cited by other articles:

				M. L. Gulley and W. Tang Laboratory Assays for Epstein-Barr Virus-Related Disease J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292. [Abstract] [Full Text] [PDF]

				M. L. Gulley, H. Fan, and S. H. Elmore Validation of Roche LightCycler Epstein-Barr Virus Quantification Reagents in a Clinical Laboratory Setting J. Mol. Diagn., November 1, 2006; 8(5): 589 - 597. [Abstract] [Full Text] [PDF]

				M. J. Espy, J. R. Uhl, L. M. Sloan, S. P. Buckwalter, M. F. Jones, E. A. Vetter, J. D. C. Yao, N. L. Wengenack, J. E. Rosenblatt, F. R. Cockerill III, et al. Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing Clin. Microbiol. Rev., January 1, 2006; 19(1): 165 - 256. [Abstract] [Full Text] [PDF]

				C. Hilscher, W. Vahrson, and D. P. Dittmer Faster quantitative real-time PCR protocols may lose sensitivity and show increased variability Nucleic Acids Res., November 27, 2005; 33(21): e182 - e182. [Abstract] [Full Text] [PDF]

				M. Islas-Ohlmayer, A. Padgett-Thomas, R. Domiati-Saad, M. W. Melkus, P. D. Cravens, M. d. P. Martin, G. Netto, and J. V. Garcia Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34+ Cells with Epstein-Barr Virus J. Virol., December 15, 2004; 78(24): 13891 - 13900. [Abstract] [Full Text] [PDF]

				N. Shivapurkar, T. Takahashi, J. Reddy, Y. Zheng, V. Stastny, R. Collins, S. Toyooka, M. Suzuki, G. Parikh, S. Asplund, et al. Presence of Simian Virus 40 DNA Sequences in Human Lymphoid and Hematopoietic Malignancies and Their Relationship to Aberrant Promoter Methylation of Multiple Genes Cancer Res., June 1, 2004; 64(11): 3757 - 3760. [Abstract] [Full Text] [PDF]